Try to access the website of the Archives of General Psychiatry and you may have to abide an ad for the antidepressant Pristiq before you can enter. (JAMA and its Archives Journals "do not endorse the advertised product," you'll be assured.)
But look for a pharma affiliation for the author of the article "Preschool Depression," Joan L. Luby, MD in the August issue and you'll be told no "financial disclosure" was reported. Not that "Dr. Luby has received grant/research support from Janssen, has given occasional talks sponsored by AstraZeneca, and has served as a consultant for Shire Pharmaceutical," as a 2006 article in Journal of the American Academy of Child and Adolescent Psychiatry says.
Even though the pharmaceutical industry has got 27 million Americans on antidepressants thanks to direct to consumer advertising--ten percent of the population--it is looking for depression in preschoolers. And guess what?
It's finding it!
It's easy to make jokes about "preschool depression"--students get it every time the alarm rings--but finding depression, "relapses," "chronicity" and "treatment resistance" in three-year-olds is not funny.
Researchers used to believe that "young children were too cognitively and emotionally immature to experience depressive effects," says Luby but now believe they can and do suffer from Major Depressive Disorder (MDD).
"The potential public health importance of identification of preschool MDD is underscored by the established unique efficacy of early intervention during the preschool period in other childhood disorders," says Luby. "Based in part on the recurrent course and the relative treatment resistance of childhood MDD, there has been increased interest in the identification of the disorder at the earliest possible stage of development."
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
